entertainment -WSS

entertainment

author：focus 2025-10-01 23:02:44 - browse：7163

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Doctors on social media are being harassed and cyberbullied

focus

entertainment

WSS

ACIP vaccine advisory panel sees its vacancies filled

Artificial intelligence use in health care faces greater scrutiny in 2024

Colonoscopy at 40? Study finds a possible benefit

ACIP vaccine advisory panel sees its vacancies filled

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Do masks work? RCTs can't tell us

focus

entertainment

hotspot

Continuity nursing helped my family in our darkest PICU moments

Why are elite athletes different? Take a look at their microbes

How to save PrEP access — and even expand it

Gene therapy has helped boys walk. Can scientists keep it that way?

Dobbs anniversary: the lost opportunity of abortion as health care

Abbott's new heart device gets FDA advisory panel nod

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cloning humans is technically possible. It's curious no one has tried

Hollywood unions extend contract negotiations for actors

3 hurdles to bringing medical devices to the U.S. market

entertainment

Why we need to separate burnout from moral injury in health care

3 hurdles to bringing medical devices to the U.S. market

With FDA staff opposed to Sarepta therapy, top official intervened

Congress might make insulin pumps more accessible to the blind

Abbott's new heart device gets FDA advisory panel nod

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

explore

entertainment

Wikipedia